Dexmedetomidine Hydrochloride Patent Expiration
Dexmedetomidine Hydrochloride was first introduced by Hospira Inc
Dexmedetomidine Hydrochloride Patents
Given below is the list of patents protecting Dexmedetomidine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Igalmi | US11806334 | Non-sedating dexmedetomidine treatment regimens | Jan 12, 2043 | Bioxcel |
| Igalmi | US11998528 | Non-sedating dexmedetomidine treatment regimens | Jan 12, 2043 | Bioxcel |
| Igalmi | US12090140 | Non-sedating dexmedetomidine treatment regimens | Jan 12, 2043 | Bioxcel |
| Igalmi | US12138247 | Non-sedating dexmedetomidine treatment regimens | Jan 12, 2043 | Bioxcel |
| Igalmi | US11890272 | Non-sedating dexmedetomidine treatment regimens | Jul 17, 2040 | Bioxcel |
| Igalmi | US11998529 | Non-sedating dexmedetomidine treatment regimens | Jul 17, 2040 | Bioxcel |
| Igalmi | US12109196 | Non-sedating dexmedetomidine treatment regimens | Jul 17, 2040 | Bioxcel |
| Igalmi | US10792246 | Film formulations containing dexmedetomidine and methods of producing them | Jun 26, 2039 | Bioxcel |
| Igalmi | US11478422 | Film formulations containing dexmedetomidine and methods of producing them | Jun 26, 2039 | Bioxcel |
| Igalmi | US11497711 | Film formulations containing dexmedetomidine and methods of producing them | Jun 26, 2039 | Bioxcel |
| Igalmi | US11517524 | Film formulations containing dexmedetomidine and methods of producing them | Jun 26, 2039 | Bioxcel |
| Igalmi | US11786508 | Use of sublingual dexmedetomidine for the treatment of agitation | Dec 29, 2037 | Bioxcel |
| Igalmi | US11839604 | Use of sublingual dexmedetomidine for the treatment of agitation | Dec 29, 2037 | Bioxcel |
| Dexmedetomidine Hydrochloride | US9649296 | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container | Apr 20, 2036 | Hq Spclt Pharma |
| Dexmedetomidine Hydrochloride | US9717796 | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container | Apr 20, 2036 | Hq Spclt Pharma |
| Precedex |
US8242158 (Pediatric) | Dexmedetomidine premix formulation | Jul 04, 2032 | Hospira |
| Precedex |
US8338470 (Pediatric) | Dexmedetomidine premix formulation | Jul 04, 2032 | Hospira |
| Precedex |
US8455527 (Pediatric) | Methods of treatment using a dexmedetomidine premix formulation | Jul 04, 2032 | Hospira |
| Precedex |
US8648106 (Pediatric) | Dexmedetomidine premix formulation | Jul 04, 2032 | Hospira |
| Precedex |
US9320712 (Pediatric) | Dexmedetomidine premix formulation | Jul 04, 2032 | Hospira |
| Precedex |
US9616049 (Pediatric) | Dexmedetomidine premix formulation | Jul 04, 2032 | Hospira |
| Precedex | US10016396 | Dexmedetomidine premix formulation | Jan 04, 2032 | Hospira |
| Precedex | US8242158 | Dexmedetomidine premix formulation | Jan 04, 2032 | Hospira |
| Precedex | US8338470 | Dexmedetomidine premix formulation | Jan 04, 2032 | Hospira |
| Precedex | US8455527 | Methods of treatment using a dexmedetomidine premix formulation | Jan 04, 2032 | Hospira |
| Precedex | US8648106 | Dexmedetomidine premix formulation | Jan 04, 2032 | Hospira |
| Precedex | US9320712 | Dexmedetomidine premix formulation | Jan 04, 2032 | Hospira |
| Precedex | US9616049 | Dexmedetomidine premix formulation | Jan 04, 2032 | Hospira |
| Precedex |
US6716867 (Pediatric) | Use of dexmedetomidine for ICU sedation |
Oct 01, 2019
(Expired) | Hospira |
| Precedex | US6716867 | Use of dexmedetomidine for ICU sedation |
Mar 31, 2019
(Expired) | Hospira |
| Precedex |
US4910214 (Pediatric) | Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist |
Jan 15, 2014
(Expired) | Hospira |
| Precedex | US4910214 | Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist |
Jul 15, 2013
(Expired) | Hospira |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Dexmedetomidine Hydrochloride's patents.
Latest Legal Activities on Dexmedetomidine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Dexmedetomidine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 20 Jan, 2021 | US9717796 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 09 Oct, 2020 | US9717796 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 24 Sep, 2020 | US9649296 |
| Patent Issue Date Used in PTA Calculation Critical
| 01 Aug, 2017 | US9717796 |
| Recordation of Patent Grant Mailed Critical
| 01 Aug, 2017 | US9717796 |
| Application ready for PDX access by participating foreign offices Critical
| 13 Jul, 2017 | US9717796 |
| Email Notification Critical
| 13 Jul, 2017 | US9717796 |
| Issue Notification Mailed Critical
| 12 Jul, 2017 | US9717796 |
| Dispatch to FDC | 28 Jun, 2017 | US9717796 |
| Application Is Considered Ready for Issue Critical
| 27 Jun, 2017 | US9717796 |
Dexmedetomidine Hydrochloride's Family Patents
